Overview

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

Status:
Completed
Trial end date:
2009-10-13
Target enrollment:
Participant gender:
Summary
This study assessed the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in participants with resistant hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Collaborators:
Great Lakes Drug Development, Inc.
Integrium
Treatments:
Eplerenone